The Fine Choices in AAV Vector System

KOWLOON, Hong Kong - Oct. 7, 2019 - PRLog -- Propagative vectors consist either of a preparation of viral particles genetically modified but competent for replication, such as vectors derived from poxviruses, or a mixture of genetically modified particles that are defective for replication and auxiliary particles that are competent for replication, conventionally the parental wild virus. These can complement in Trans the lack of replication of the AAV vector system.

Among the potential dangers, are considered particularly serious:

• The possibility of accidental production of a highly pathogenic recombinant strain for humans, animals or plants
• The uncontrollable spread of an artificial viral strain, irrespective of its pathogenicity
• The medical or industrial use of viral vector preparations contaminated with unidentified and undetected viral species.
• Two types of viral vectors can be contrasted depending on whether the ability of the virus to propagate indefinitely has been retained or suppressed in the vector. You need the best AAV production for the same

Non Propagative Vectors

Non-propagative vectors consist of a pure prior preparation of viral particles defective for replication. Most of the vectors derived from MLV retroviruses, lent viruses, Associated Virus (AAV) and adenoviruses fall into this category. The confinement conditions of the vectors that are defective for replication are equivalent to or less strict than those of the wild virus.

They depend on the assessment of the risk that these vectors accidentally acquire an uncontrollable propagation capacity. The production uses trans-complementation cellular systems that transitively or constitutively express the viral genes necessary for the assembly and replication of the viral particles.

During this phase, the phenotype is that of a propagative vector and the risks of accidental dissemination are equivalent. The confinement required during this phase is therefore that of a propagating vector from the same viral strain. For the AAV gene therapy aav transduction this is important.

Last Words
During the production phase, genetic recombination with Trans complementing sequences or contamination of the preparation with wild particles may be feared. In the use phase, the eventualities of Tran's complementation by a cell protein capable of substituting for a viral protein and infection with the parental wild-type virus having incorporated the vector are considered. The assessment of this risk takes into account the nature of the virus from which the vector is derived, the design of the vector, the methods of its production, the number of vector particles produced, the number of transduced target cells and the nature of the virus.

Website: https://www.genemedi.net/i/aav-packaging